Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells

DNA and Cell Biology

Volumn 31, Issue 11, 2012, Pages 1572-1579

  Colamartino, Monica ^a   Padua, Luca ^b,c   Meneghini, Carlo ^a   Leone, Stefano ^a   Cornetta, Tommaso ^a   Testa, Antonella ^d   Cozzi, Renata ^a  

^a ROMA TRE UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^d ENEA Research Centre   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; LEVODOPA; REACTIVE OXYGEN METABOLITE;

ARTICLE; CORPUS STRIATUM; CYTOTOXICITY; DNA DAMAGE; DRUG BIOAVAILABILITY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUROBLASTOMA CELL; NEUROPROTECTION; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANTIPARKINSON AGENTS; CARBIDOPA; CELL LINE, TUMOR; CELL SURVIVAL; COMET ASSAY; DNA DAMAGE; DOPA DECARBOXYLASE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; HYDROGEN PEROXIDE; LEVODOPA; NEUROBLASTOMA; OXIDANTS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TIME FACTORS;

EID: 84868025710     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2011.1546     Document Type: Article

References (37)

1. Collins, A.R. (2004). The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 26, 249-261.
2. Collins, A.R., Dusinska, M., Gedik, C.M., and Stetina, R. (1996). Oxidative damage to DNA: do we have a reliable biomarker? Environ Health Perspect 104 Suppl 3, 465-469.
3. Collins, A.R., Duthie, S.J., and Dobson, V.L. (1993). Direct enzymic detection of endogenous oxidative base damage in human lymphocyte DNA. Carcinogenesis 14, 1733-1735.
4. Cornetta, T., Palma, S., Aprile, I., Padua, L., Tonali, P., Testa, A., and Cozzi, R. (2009). Levodopa therapy reduces DNA damage in peripheral blood cells of patients with Parkinson's disease. Cell Biol Toxicol 25, 321-330.
5. Festa, F., Cristaldi, M., Ieradi, L.A., Moreno, S., and Cozzi, R. (2003). The Comet assay for the detection of DNA damage in Mus spretus from Donana National Park. Environ Res 91, 54-61.
6. Goole, J., and Amighi, K. (2009). Levodopa delivery systems for the treatment of Parkinson's disease: an overview. Int J Pharm 380, 1-15.
7. Hadjiconstantinou, M., and Neff, N.H. (2008). Enhancing aromatic L-amino acid decarboxylase activity: implications for L-DOPA treatment in Parkinson's disease. CNS Neurosci Ther 14, 340-351.
8. Han, S.K., Mytilineou, C., and Cohen, G. (1996). L-DOPA upregulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 66, 501-510.
9. Hattoria, N., Wanga, M., Taka, H., Fujimura, T., Yoritaka, A., Kubo, S., and Mochizuki, H. (2009). Toxic effects of dopamine metabolism in Parkinson's disease. Parkinsonism Relat Disord 15 Suppl 1, S35-S38.
10. Hoyt, K.R., Reynolds, I.J., and Hastings, T.G. (1997). Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: interactions with and differences from glutamateinduced cell death. Exp Neurol 143, 269-281.
11. Jiang, Y., Pei, L., Li, S., Wang, M., and Liu, F. (2008). Extracellular dopamine induces the oxidative toxicity of SH-SY5Y cells. Synapse 62, 797-803.
12. Jones, D.C., Gunasekar, P.G., Borowitz, J.L., and Isom, G.E. (2000). Dopamine-induced apoptosis is mediated by oxidative stress and Is enhanced by cyanide in differentiated PC12 cells. J Neurochem 74, 2296-2304.
13. Kuoppamaki, M., Korpela, K., Marttila, R., Kaasinen, V., Hartikainen, P., Lyytinen, J., Kaakkola, S., Hanninen, J., Loyttyniemi, E., Kailajarvi, M., et al. (2009). Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 65, 443-455.
14. Lyras, L., Zeng, B.Y., McKenzie, G., Pearce, R.K., Halliwell, B., and Jenner, P. (2002). Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigrostriatal pathway in normal cynomologus monkeys. J Neural Transm 109, 53-67.
15. Mena, M.A., Davila, V., and Sulzer, D. (1997). Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/ cortical astrocyte cocultures. J Neurochem 69, 1398-1408.
16. Miyazaki, I., and Asanuma, M. (2008). Dopaminergic neuronspecific oxidative stress caused by dopamine itself. Acta Med Okayama 62, 141-150.
17. Muller, T. (2009). Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference. Patient Prefer Adherence 3, 51-59.
18. Mytilineou, C., Han, S.K., and Cohen, G. (1993). Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem 61, 1470-1478.
19. Mytilineou, C., Walker, R.H., JnoBaptiste, R., and Olanow, C.W. (2003). Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther 304, 792-800.
20. Nagatsua, T., and Sawadab, M. (2009). L-dopa therapy for Parkinson's disease: past, present, and future. Parkinsonism Relat Disord 15 Suppl 1, S3-S8.
21. Nakabeppu, Y., Tsuchimoto, D., Yamaguchi, H., and Sakumi, K. (2007). Oxidative damage in nucleic acids and Parkinson's disease. J Neurosci Res 85, 919-934.
22. Nyholm, D. (2006). Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 45, 109-136.
23. Obata, T., and Yamanaka, Y. (1996). Protective effect of carbidopa on hydroxyl radical generation in the rat striatum by dopamine. Neurosci Lett 221, 13-16.
24. Olanow, C.W., Agid, Y., Mizuno, Y., Albanese, A., Bonuccelli, U., Damier, P., De Yebenes, J., Gershanik, O., Guttman, M., Grandas, F., et al. (2004). Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19, 997-1005.
25. Olanow, C.W., Gauger, L.L., and Cedarbaum, J.M. (1991). Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Ann Neurol 29, 556-559.
26. Oli, R.G., Fazeli, G., Kuhn, W., Walitza, S., Gerlach, M., and Stopper, H. (2010). No increased chromosomal damage in LDOPA- treated patients with Parkinson's disease: a pilot study. J Neural Transm 117, 737-746.
27. Poewe, W., Antonini, A., Zijlmans, J.C., Burkhard, P.R., and Vingerhoets, F. (2010). Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging 5, 229-238.
28. Prigione, A., Begni, B., Galbussera, A., Beretta, S., Brighina, L., Garofalo, R., Andreoni, S., Piolti, R., and Ferrarese, C. (2006). Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage. Neurobiol Dis 23, 36-43.
29. Schapira, A.H. (2008). The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. Mov Disord 23 Suppl 3, S515-S520.
30. Seeberger, L.C., and Hauser, R.A. (2007). Optimizing bioavailability in the treatment of Parkinson's disease. Neuropharmacology 53, 791-800.
31. Shi, Y.L., Benzie, I.F., and Buswell, J.A. (2002). L-DOPA oxidation products prevent H2O2-induced oxidative damage to cellular DNA. Life Sci 71, 3047-3057.
32. Solla, P., Cannas, A., Marrosu, F., and Marrosu, M.G. (2010). Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/ entacapone (Stalevo). Neuropsychiatr Dis Treat 6, 483-490.
33. Spina, M.B., and Cohen, G. (1989). Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci U S A 86, 1398-1400.
34. Stocchi, F., Vacca, L., Ruggieri, S., and Olanow, C.W. (2005). Intermittent vs. continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 62, 905-910.
35. Tayarani-Binazir, K.A., Jackson, M.J., Fisher, R., Zoubiane, G., Rose, S., and Jenner, P. (2010). The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTPtreated common marmoset. Eur J Pharmacol 635, 109-116.
36. Xie, H.R., Hu, L.S., and Li, G.Y. (2010). SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease. Chin Med J (Engl) 123, 1086-1092.
37. Ziv, I., Zilkha-Falb, R., Offen, D., Shirvan, A., Barzilai, A., and Melamed, E. (1997). Levodopa induces apoptosis in cultured neuronal cells - a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Mov Disord 12, 17-23.